Press Releases

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

Study on the immunotherapy developed at Roswell Park is the second phase 2 trial in a major cancer indication

Tuesday, May 5, 2026 - 08:00 am

Study shows that a key regulator protein plays a role in the development of the most aggressive form of prostate cancer

Monday, May 4, 2026 - 09:00 am

Drug designed to stop breast cancer cells from multiplying

Wednesday, April 29, 2026 - 02:30 pm

Weeklong training sessions slated for May and October at Roswell Park

Tuesday, April 28, 2026 - 08:00 am

Research is significant for future prevention and early detection of pancreatic cancer

Thursday, April 23, 2026 - 08:00 am

Findings shared at AACR Annual Meeting on new approach exploits core biological weakness of p53 mutant cancer cells

Wednesday, April 22, 2026 - 10:00 am

Cancer center ranks in the top quarter of 600 employers recognized nationally

Tuesday, April 21, 2026 - 11:00 am

Roswell Park physicians highlight trends that are shaping endometrial cancer risk, outcomes and opportunities for early intervention

Monday, April 20, 2026 - 09:00 am

Roswell Park study links T-DXd to longer overall survival in patients with HER2-positive metastatic disease

Sunday, April 19, 2026 - 06:00 pm